Boston Scientific BSX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $3.5B+1.1% | $3.47B+4.1% | $3.33B-0.4% | $3.34B+5.8% | $3.16B+6.0% | |
| MedSurg | $1.7B-5.7% | $1.8B+5.1% | $1.71B0.0% | $1.71B+6.5% | $1.61B-1.7% | |
| Net Sales by Business | ||||||
| Cardiovascular | $3.5B+0.7% | $3.48B+4.0% | $3.34B-0.1% | $3.35B+8.4% | $3.09B+4.9% | |
| MedSurg | $1.7B-6.0% | $1.81B+5.1% | $1.72B+0.3% | $1.72B+8.8% | $1.58B-2.7% | |
| Total assets of reportable segments by Business | ||||||
| Cardiovascular | $8.25B+3.2% | $8B+2.6% | $7.8B+4.0% | $7.5B+1.1% | $7.41B+4.6% | |
| MedSurg | $3.73B+9.8% | $3.39B0.0% | $3.39B+1.8% | $3.33B+6.5% | $3.13B+1.1% | |
| Other segment items, percentage of net sale by Business | ||||||
| Cardiovascular | 0.2%— | —— | 0.2%0.0pp | 0.2%0.0pp | 0.2%— | |
| MedSurg | 0.3%— | —— | 0.3%-0.2pp | 0.5%+0.2pp | 0.3%— | |
| Other segment items by Business | ||||||
| Cardiovascular | $7M0.0% | $7M+16.7% | $6M0.0% | $6M0.0% | $6M+20.0% | |
| MedSurg | $5M+150% | $2M-60.0% | $5M-37.5% | $8M+33.3% | $6M+20.0% | |
| Segment operating income, percentage of net sale by Business | ||||||
| Cardiovascular | 32.1%— | —— | 34.1%+2.2pp | 31.9%-1.9pp | 33.8%+33.5pp | |
| MedSurg | 31.3%— | —— | 33%-1.9pp | 34.9%+1.6pp | 33.3%— | |
| Operating Income (Loss), Adjusted by Business | ||||||
| Cardiovascular | $1.13B+7.1% | $1.05B-7.5% | $1.14B+6.6% | $1.07B-0.3% | $1.07B+17.1% | |
| MedSurg | $533M-7.3% | $575M+1.6% | $566M-5.5% | $599M+11.8% | $536M-4.8% | |
| Selling, general and administrative expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 27.4%+27.1pp | 0.3%-27.3pp | 27.6%+0.4pp | 27.2%-0.5pp | 27.7%— | |
| MedSurg | 32.8%— | —— | 31%+0.8pp | 30.2%-1.6pp | 31.8%— | |
| Cost of products sold by Business | ||||||
| Cardiovascular | $1.07B+2.2% | $1.04B+12.3% | $930M-11.1% | $1.05B+13.0% | $926M+1.6% | |
| MedSurg | $478M-9.6% | $529M+9.5% | $483M+2.8% | $470M+8.0% | $435M-4.8% | |
| Cost of products sold, percentage of net sale by Business | ||||||
| Cardiovascular | 30.5%+30.4pp | 0.1%-27.8pp | 27.9%-3.4pp | 31.3%+2.0pp | 29.3%— | |
| MedSurg | 28.1%+27.6pp | 0.5%-27.7pp | 28.2%+0.8pp | 27.4%+0.4pp | 27%+26.7pp | |
| Research and development expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 9.8%+9.4pp | 0.4%-9.7pp | 10.1%+0.7pp | 9.4%+0.4pp | 9%+8.9pp | |
| MedSurg | 7.5%+7.4pp | 0.1%-7.4pp | 7.5%+0.5pp | 7%-0.5pp | 7.5%+7.4pp | |
| Selling, general and administrative expenses by Business | ||||||
| Cardiovascular | $959M-3.1% | $990M+7.6% | $920M+1.3% | $908M+4.0% | $873M-0.1% | |
| MedSurg | $557M-0.5% | $560M+5.5% | $531M+2.7% | $517M+1.0% | $512M+6.0% | |
| Impact of foreign currency fluctuations and purchase price and other adjustments by Business | ||||||
| Cardiovascular | -$14M-256% | $9M— | —— | $62M+107% | $30M+135% | |
| MedSurg | -$5M-156% | $9M+800% | $1M-96.2% | $26M+52.9% | $17M+231% | |
| Research and development expenses by Business | ||||||
| Cardiovascular | $343M-8.5% | $375M+11.3% | $337M+7.0% | $315M+11.3% | $283M+2.5% | |
| MedSurg | $127M-8.0% | $138M+7.8% | $128M+6.7% | $120M-0.8% | $121M-5.5% | |
| Goodwill by Business | ||||||
| Cardiovascular | $10.56B-0.1% | $10.57B+0.4% | $10.53B-0.2% | $10.55B+7.2% | $9.84B+2.4% | |
| MedSurg | $7.98B+3.5% | $7.71B+0.3% | $7.69B+2.1% | $7.53B+0.3% | $7.5B+0.2% | |
| Depreciation by Business | ||||||
| Cardiovascular | $89M-15.2% | $105M+18.0% | $89M+7.2% | $83M+6.4% | $78M-14.3% | |
| MedSurg | $29M-6.5% | $31M+6.9% | $29M+3.6% | $28M+3.7% | $27M-12.9% | |
| Goodwill acquired by Business | ||||||
| Cardiovascular | $0-100% | $37M— | $0-100% | $648M+216% | $205M+3,317% | |
| MedSurg | $274M+1,857% | $14M-91.2% | $159M— | $0— | $0-100% | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $578M-1.4% | $586M+1.4% | $578M-2.0% | $590M+2.1% | $578M+2.1% | |
| Electrophysiology | $905M+1.7% | $890M+2.9% | $865M+3.0% | $840M+15.1% | $730M+12.5% | |
| Endoscopy | $736M-3.0% | $759M+1.6% | $747M+1.4% | $737M+9.5% | $673M-2.6% | |
| Interventional Cardiology & Vascular Therapies | $1.24B— | —— | $686M-6.2% | $731M-35.0% | $1.12B+68.3% | |
| Interventional Oncology & Embolization | $268M— | —— | —— | —— | $228M+6.5% | |
| Neuromodulation | $318M-4.5% | $333M+13.7% | $293M-3.3% | $303M+11.8% | $271M-9.4% | |
| Urology | $646M-9.9% | $717M+5.1% | $682M+0.9% | $676M+6.8% | $633M+0.5% | |
| Watchman | $506M-5.4% | $535M+4.5% | $512M+5.3% | $486M+14.4% | $425M+2.9% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $803M+1.9% | $788M-1.7% | $802M+1.5% | $790M+12.7% | $701M+2.5% | |
| Europe, Middle East and Africa | $932M-0.1% | $933M+17.7% | $793M-9.7% | $878M+3.8% | $846M+1.9% | |
| Latin America and Canada | $185M+3.4% | $179M+2.3% | $175M+3.6% | $169M+9.0% | $155M0.0% | |
| U.S. | $3.28B-3.0% | $3.39B+2.8% | $3.29B+2.2% | $3.22B+8.9% | $2.96B+2.3% | |
| Long-Lived Assets by Geography | ||||||
| Costa Rica | $640M+0.5% | $637M+7.4% | $593M+3.3% | $574M+3.1% | $557M+5.1% | |
| Ireland | $750M0.0% | $750M+6.1% | $707M+0.9% | $701M+7.0% | $655M+3.8% | |
| U.S. | $1.95B+1.5% | $1.92B+5.9% | $1.81B+18.4% | $1.53B+0.5% | $1.52B+4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
